Table 3 Comparison between survivors and non-survivors with IM
Characteristics | Survivor (n = 22) | Non-survivor (n = 10) | P value |
|---|---|---|---|
Demographic characteristics | |||
Sex, male to female | 4:18 | 3:7 | 0.45 |
Age, years, mean ± SD | 41.6 ± 15.6 | 44.2 ± 16.8 | 0.68 |
Diabetes mellitus, n (%) | 2(9.1) | 2(20.0) | 0.39 |
Interstitial pneumonia, n (%) | 4(18.2) | 2(20.0) | 0.90 |
Nephritis, n (%) | 12(54.5) | 7(70.0) | 0.41 |
Laboratory data | |||
Leukopenia, n (%) | 1(4.5) | 3(30.0) | 0.04* |
Lymphopenia, n (%) | 13(59.1) | 10(100) | 0.02* |
Anemia, n (%) | 12(54.5) | 8(80.0) | 0.17 |
Hypoalbuminemia, n (%) | 14(63.6) | 9(90.0) | 0.12 |
Elevated serum creatinine, n (%) | 6(27.3) | 7(70.0) | 0.02* |
Co-infection, n (%) | 4(18.2) | 7(70.0) | 0.004* |
Co-infection with multiple agents, n (%) | 1(4.5) | 2(20.0) | 0.22 |
Co-infection in multiple sites, n (%) | 0(0) | 5(50.0) | < 0.001* |
Treatments prior to IM | |||
Median-to-high dose of GC, n (%) | 7(31.8) | 4(40.0) | 0.65 |
CYC, n (%) | 4(18.2) | 5(50.0) | 0.06 |
MMF, n (%) | 1(4.5) | 2(20.0) | 0.16 |